Weight loss peptide
You are deciding between two options.
Reference and calculator, not medical advice. Dosing figures below are transcribed from FDA-approved prescribing information and link back to it. Last reviewed August 2026.
The most important thing to know about "weight loss peptides" as a category is that it is not one. Every GLP-1 medication on this site is itself a peptide — semaglutide and tirzepatide both are. So the question is never peptide versus GLP-1; it is which specific peptide, and whether it is an approved product with a label you can read or something sold outside that framework entirely.
What "Peptides" actually is
Not a category with a shared meaning. Marketed peptide products range from FDA-approved drugs to compounded preparations to research chemicals sold without approval.
- FDA-approved medication
- No
- Approved for
- Depends entirely on the specific peptide. Several sold for body composition — including BPC-157 — have been placed by the FDA in a category flagged for significant safety risk.
- Difference that matters
- GLP-1 medications are themselves peptides. The question is not peptide versus GLP-1, but which specific peptide, and whether it is an approved product with a label you can read.
This page describes what each thing is and what it is approved for. It does not compare how well they work, because that is a question for a prescriber with your history in front of them.
That distinction is where the real divide sits. Products marketed under peptide branding span a range from FDA-approved drugs through compounded preparations to research chemicals sold with no approval at all — and several sold for body composition have been placed by the FDA in a category flagged for significant safety risk. Those are not variations in quality within one category; the first has prescribing information and the last has none.
Two different regulatory paths
Which one a product travelled determines what had to be proved before it could be sold.
- Prescription drug
- FDA reviews safety and efficacy before it can be sold. Carries prescribing information with dosing, contraindications and adverse-reaction rates. Every medication on this site.
- Dietary supplement
- No FDA approval before sale. The manufacturer is responsible for its own safety substantiation, and structure/function claims carry a disclaimer stating the product is not intended to diagnose, treat, cure or prevent disease. Products sold as GLP-1 "support", "booster" or "daily".
This is a description of two legal pathways, not a judgement about any product. A supplement being on the supplement path is not a criticism of it — it is the reason the two categories cannot be compared on a price-per-month basis the way two prescription options can.
Three questions that settle it for any brand
New products appear constantly. These work on all of them.
- 1. Does it require a prescription?Every approved GLP-1 receptor agonist does. If you can add it to a cart without one, it is not one of them. This single question settles most cases.
- 2. Is there prescribing information?Approved drugs have a label on DailyMed listing dosing, contraindications and adverse reaction rates. Supplements do not have one, because they were never required to produce it.
- 3. Does the claim carry the supplement disclaimer?The sentence about not being intended to diagnose, treat, cure or prevent disease is required on supplement structure/function claims. Its presence tells you which regulatory path the product is on.
Side-by-side
Structural facts from each product’s prescribing information.
| Product | Active ingredient | Indication | Frequency | Start | Max labelled | Steps to max |
|---|---|---|---|---|---|---|
| Zepbound Eli Lilly | Tirzepatide | Weight management | Weekly | 2.5 mg | 15 mg | 6 |
| Mounjaro Eli Lilly | Tirzepatide | Type 2 diabetes | Weekly | 2.5 mg | 15 mg | 6 |
| Wegovy Novo Nordisk | Semaglutide | Weight management | Weekly | 0.25 mg | 2.4 mg | 5 |
| Wegovy tablets Novo Nordisk | Semaglutide (oral) | Weight management | Daily | 1.5 mg | 25 mg | 4 |
| Ozempic Novo Nordisk | Semaglutide | Type 2 diabetes | Weekly | 0.25 mg | 2 mg | 4 |
| Rybelsus Novo Nordisk | Semaglutide (oral) | Type 2 diabetes | Daily | 3 mg | 14 mg | 3 |
| Saxenda Novo Nordisk | Liraglutide | Weight management | Daily | 0.6 mg | 3 mg | 5 |
| Trulicity Eli Lilly | Dulaglutide | Type 2 diabetes | Weekly | 0.75 mg | 4.5 mg | 4 |
Common questions
- Are research peptides the same molecules?
- A product sold for research use is not sold as a medicine, is not dispensed against a prescription, and carries no prescribing information. Whatever is in the vial, there is no label defining its dose or its adverse reaction profile.
- Why does this site not compare specific ones?
- Because it only publishes figures that trace back to a prescribing information document. For products without one there is nothing to transcribe, and inventing a comparison would be exactly the thing this site exists not to do.
- Is semaglutide a peptide?
- Yes — which is why the framing of the question rarely survives contact with the answer. The approved GLP-1 medications are peptide drugs that went through FDA review.
Sources and last review
Every dosing figure on this page is transcribed from an FDA-approved label and links back to it. Conversions are arithmetic you can repeat by hand. Nothing here is reviewed by a clinician, and this site does not employ one — which is exactly why what I do publish stays traceable to its source.
- Zepbound (Tirzepatide) prescribing information — Eli Lilly, label revised 6 May 2026, checked 7 August 2026
- Mounjaro (Tirzepatide) prescribing information — Eli Lilly, label revised 6 May 2026, checked 7 August 2026
- Wegovy (Semaglutide) prescribing information — Novo Nordisk, label revised 30 June 2026, checked 7 August 2026
- Ozempic (Semaglutide) prescribing information — Novo Nordisk, label revised 10 June 2026, checked 7 August 2026
- Rybelsus (Semaglutide) prescribing information — Novo Nordisk, label revised 20 May 2026, checked 7 August 2026
- Saxenda (Liraglutide) prescribing information — Novo Nordisk, label revised 15 June 2026, checked 7 August 2026
- Trulicity (Dulaglutide) prescribing information — Eli Lilly, label revised 25 March 2026, checked 7 August 2026
Transcribed from the labels above and checked by me — Gavin, who builds this site, takes a GLP-1, and is not a clinician. Last reviewed August 2026. Found an error? [email protected] — I treat corrections as bugs. How this site is built and funded.
Also searched as: fat loss peptide · best fat loss peptide
Related
- Tirzepatide vs semaglutide for weight lossCompare
- GLP-1 vs glp-2 weight lossCompare
- Peptides vs GLP-1 for weight lossCompare
- Tirzepatide dosing for weight loss in unitsDosing
- Tirzepatide dosage for weight lossDosing
- GLP-1 dosage for weight lossDosing
- GLP-1 drops dosage for weight lossDosing
- GLP-1 weight loss calculatorDosing